Moneycontrol PRO

Black Friday Sale

Black Friday Sale

you are here: HomeNewsBusinessIPOReporter's Take | Why Biocon Biologics is valued at $3 bn?

SHOW NAMES

Trending Topics

X

business

Reporter's Take | Why Biocon Biologics is valued at $3 bn?

Moneycontrol’s Jerome Anthony talks to pharma correspondent Viswanath Pilla to find out why the company has received such a high valuation.

first published: Jan 7, 2020 09:29 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

FSS Simply Payments 2025 | AI in Payments: Building a Governance-First Future.
Live: Nifty reclaims 25,900, snaps 3-day losing streak; rupee falls to fresh low | Closing Bell
Live: Can Nifty snap 3-day losing streak after Fed's policy outcome? | Opening Bell
Live: Nifty slips below 24,800 as breadth weakens; SMIDs underperform | Closing Bell

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347